Back to Search
TOMASZ M. BEER MD
MD
Medical Oncology Physician
NPI: 1669487179IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
MD17740(OR)
Education
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
Class of 1991
Research & Publications (20)
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.
PMID 17960793·Cancer·2008
4-observational
Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.
PMID 18824433·Clin Genitourin Cancer·2008
3-trial
Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.
PMID 18501081·Clin Genitourin Cancer·2008
3-trial
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.
PMID 18428198·Cancer·2008
4-observational
Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer.
PMID 17645830·Clin Genitourin Cancer·2007
8-other
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel.
PMID 17618407·Invest New Drugs·2007
3-trial
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer.
PMID 17066293·Cancer Chemother Pharmacol·2007
3-trial
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
PMID 17308271·J Clin Oncol·2007
4-observational
Effect of calcitriol on prostate-specific antigen in vitro and in humans.
PMID 16675575·Clin Cancer Res·2006
8-other
Testosterone loss and estradiol administration modify memory in men.
PMID 16406889·J Urol·2006
8-other
Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies.
PMID 16688776·Cancer·2006
3-trial
The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894.
PMID 16804926·Cancer·2006
8-other
Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study.
PMID 17001181·Anticancer Drugs·2006
3-trial
Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer.
PMID 16278401·Clin Cancer Res·2005
3-trial
ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere.
PMID 16104901·BJU Int·2005
3-trial
Rationale for the development and current status of calcitriol in androgen-independent prostate cancer.
PMID 15668801·World J Urol·2005
6-review
High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer.
PMID 15596926·Am J Clin Oncol·2004
3-trial
Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy.
PMID 15598784·Cancer Epidemiol Biomarkers Prev·2004
3-trial
Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer.
PMID 14977829·Clin Cancer Res·2004
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3181 SW SAM JACKSON PARK RD
PORTLAND, OR 97239 - Phone
- (503) 494-6594
Quick Facts
- NPI
- 1669487179
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 35
- Publications
- 20
Are you this provider?
Claim Your Profile